Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Clearside Biomedical (Nasdaq: CLSD) announced the initiation of the Phase 2b ODYSSEY Trial for CLS-AX targeting wet AMD, with enrollment expected to commence in Q2 2023. The company highlighted favorable safety data from its OASIS Phase 1/2a trial, showing 67% of participants remained treatment-free for at least six months. Financially, Clearside reported a significant decline in revenues, with Q4 2022 revenue at $330,000, down from $25.7 million in Q4 2021, primarily due to a one-time milestone payment the previous year. The net loss for the year reached $32.9 million, or $0.55 per share, compared to a net income of $376,000 in 2021.
- Initiation of the Phase 2b ODYSSEY Trial for CLS-AX in wet AMD.
- OASIS trial showed positive safety data and durability of treatment.
- 67% of OASIS participants were treatment-free for at least 6 months.
- Continued training of over 1,000 retinal specialists for SCS injection.
- Q4 2022 revenue of $330,000, a decline of $25.4 million from Q4 2021.
- Net loss of $32.9 million for 2022, compared to a net income of $376,000 in 2021.
- R&D expenses increased to $19.6 million in 2022 from $18.5 million in 2021.
- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 -
- Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months -
- Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS®) Injection Procedure Using FDA-Approved XIPERE® -
- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -
ALPHARETTA, Ga., March 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
“Over the past year, we have reinforced Clearside’s leadership position in the delivery of therapeutics into the suprachoroidal space through our in-office, repeatable, non-surgical procedure utilizing our proprietary SCS Microinjector®,” said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer. “With the launch of XIPERE® in the United States in 2022 by our partner, Bausch + Lomb, we believe there is increasing acceptance of treating serious retinal diseases through the SCS. Importantly, we also made excellent progress with our internal CLS-AX (axitinib injectable suspension) wet AMD clinical program.”
Dr. Lasezkay continued, “The positive data from our OASIS Phase 1/2a clinical trial reinforces our belief that CLS-AX has the potential to reduce treatment burden in patients with wet AMD while maintaining stable visual acuity. CLS-AX was well tolerated and demonstrated an excellent safety profile across all timepoints and doses in the trial. Importantly, the full extension data showed promising durability, with
“Given this favorable CLS-AX Phase 1/2a data, as previously announced, we will conduct a randomized, controlled, double-masked, Phase 2b clinical trial, called ODYSSEY, in wet AMD participants. Based on the draft guidance on wet AMD drug development released on February 24, 2023, by the U.S. Food & Drug Administration (FDA), we plan to adjust our trial design to use on-label aflibercept dosing in the comparator arm of ODYSSEY. We expect a seamless transition to this adjusted trial design and plan to open trial enrollment in the second quarter of 2023,” concluded Dr. Lasezkay.
Key Highlights
- Favorable safety data, durability, and biologic effect were reported from OASIS, Clearside’s U.S.-based, open-label, dose-escalation Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).
- Clearside’s XIPERE® (triamcinolone acetonide injectable suspension) commercialization partner, Bausch + Lomb, continues to expand outreach and training with over 1,000 retinal physicians trained to date in the use of the SCS Microinjector for suprachoroidal delivery.
- Clearside’s licensing partner, Aura Biosciences, finalized its global Phase 3 clinical trial design in alignment with regulatory agencies and selected suprachoroidal route of administration to evaluate the efficacy and safety of belzupacap saratalocan (bel-sar) in early-stage choroidal melanoma, a life-threatening rare disease with no approved therapies.
- Former Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., transitioned to an external advisory role for Clearside as Chief Medical Advisor-Retina and Chair of the Scientific Advisory Board, continuing to share his medical expertise as a practicing retinal specialist and providing counsel on Clearside’s suprachoroidal development programs.
- Promising data results were presented at major medical meetings on behalf of partners utilizing Clearside’s proprietary SCS Microinjector to administer ocular gene therapy and oncology agents.
- Multiple presentations featuring Clearside’s proprietary suprachoroidal space injection platform were highlighted at global conferences, including the Macula Society Annual Meeting; Angiogenesis, Exudation, and Degeneration Virtual Conference; American Academy of Ophthalmology; Retina Society Annual Scientific Meeting; and, OIS Retina Summit.
Fourth Quarter 2022 Financial Results
Clearside’s license and other revenue for the fourth quarter of 2022 was
Cost of goods sold for the fourth quarter of 2022 was
Research and development expenses for the fourth quarter of 2022 were
General and administrative expenses for the fourth quarter of 2022 were
Net loss for the fourth quarter of 2022 was
Full Year 2022 Financial Results
Clearside’s license and other revenue for the year ended December 31, 2022, was
Cost of goods sold for the year ended December 31, 2022, was
Research and development expenses for the year ended December 31, 2022, were
General and administrative expenses for the year ended December 31, 2022, were
Net loss for the year ended December 31, 2022, was
As of December 31, 2022, Clearside’s cash and cash equivalents totaled
Conference Call & Webcast Details
Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telephone, please register in advance using the link provided in the event listing. The Company suggests participants log in 15 minutes in advance of the event.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of CLS-AX, timeline for initiating the ODYSSEY Phase 2b clinical trial for CLS-AX, the potential benefits of CLS-AX and other product candidates using Clearside’s SCS Microinjector® and Clearside’s ability to fund its operations into the second quarter of 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, uncertainties regarding the COVID-19 pandemic and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (SEC) on March 11, 2022, Clearside’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the SEC on November 9, 2022 and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
-Financial Tables Follow-
CLEARSIDE BIOMEDICAL, INC.
Selected Financial Data
(in thousands, except share and per share data)
(unaudited)
| Statements of Operations Data | Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| License and other revenue | $ | 330 | $ | 25,687 | $ | 1,327 | $ | 29,575 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of goods sold | 204 | — | 204 | — | ||||||||||||
| Research and development | 5,027 | 3,840 | 19,630 | 18,537 | ||||||||||||
| General and administrative | 3,169 | 3,140 | 11,770 | 11,665 | ||||||||||||
| Total operating expenses | 8,400 | 6,980 | 31,604 | 30,202 | ||||||||||||
| (Loss) income from operations | (8,070 | ) | 18,707 | (30,277 | ) | (627 | ) | |||||||||
| Other income | 449 | 2 | 669 | 1,003 | ||||||||||||
| Non-cash interest expense on liability related to the sales of future royalties | (2,042 | ) | — | (3,339 | ) | — | ||||||||||
| Net (loss) income | $ | (9,663 | ) | $ | 18,709 | $ | (32,947 | ) | $ | 376 | ||||||
| Net (loss) income per share of common stock — basic and diluted | $ | (0.16 | ) | $ | 0.31 | $ | (0.55 | ) | $ | 0.01 | ||||||
| Weighted average shares outstanding — basic | 60,412,700 | 59,669,759 | 60,204,862 | 58,491,986 | ||||||||||||
| Weighted average shares outstanding — diluted | 60,412,700 | 61,182,414 | 60,204,862 | 59,906,602 | ||||||||||||
| Balance Sheet Data | December 31, | December 31, | |||||
| 2022 | 2021 | ||||||
| Cash and cash equivalents | $ | 48,258 | $ | 30,436 | |||
| Accounts receivable | — | 10,000 | |||||
| Total assets | 51,303 | 42,903 | |||||
| Liabilities related to the sales of future royalties, net | 33,977 | — | |||||
| Total liabilities | 40,696 | 4,928 | |||||
| Total stockholders’ equity | 10,607 | 37,975 | |||||
Source: Clearside Biomedical, Inc.
FAQ
What were Clearside Biomedical's financial results for Q4 2022?
What is the CLS-AX Phase 2b ODYSSEY Trial?
How did the company's revenue change in 2022?
What were the key financial metrics for Clearside in 2022?
